Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Puma Biotechnology Inc - Common Stock (NQ:PBYI)

6.230 -0.170 (-2.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Puma Biotechnology Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  During Monday's session, 50 stocks hit new 52-week highs. 
Via Benzinga
News headline image
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings ↗
 
Via Benzinga
News headline image
S&P 500 Down 1%; Crude Oil Drops Sharply ↗
U.S. stocks traded lower midway through trading, with the S&P 500 dropping around 1% on Thursday. 
Via Benzinga
News headline image
Short Volatility Alert: Puma Biotechnology, Inc. ↗
On Tuesday, shares of Puma Biotechnology, Inc. (NASDAQ: PBYI) experienced volatile short activity. After the activity, the stock price went up +3.99% to $3.26. The overall sentiment for PBYI has been... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers 
Via Benzinga
News headline image
Puma Biotechnology Reports Third Quarter 2022 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology's Earnings Outlook ↗
Puma Biotechnology (NASDAQ:PBYI) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Puma... 
Via Benzinga
News headline image
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday ↗
Gainers 
Via Benzinga
News headline image
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer ↗
 
Via Benzinga
News headline image
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Second Quarter 2022 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket’ Trial of Neratinib at the ASCO 2022 Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
69 Biggest Movers From Friday ↗
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per... 
Via Benzinga
News headline image
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Reports First Quarter 2022 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
News headline image
Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting
From Puma Biotechnology, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.